P53 negatively regulates the osteogenic differentiation in jaw bone marrow MSCs derived from diabetic osteoporosis
- PMID: 37096002
- PMCID: PMC10121411
- DOI: 10.1016/j.heliyon.2023.e15188
P53 negatively regulates the osteogenic differentiation in jaw bone marrow MSCs derived from diabetic osteoporosis
Abstract
Patients with diabetic osteoporosis (DOP) often suffer from poor osseointegration of artificial implants, which is a challenge that affects implant outcomes. The osteogenic differentiation ability of human jaw bone marrow mesenchymal stem cells (JBMMSCs) is the key to implant osseointegration. Studies have shown that the microenvironment of hyperglycemia affects the osteogenic differentiation of mesenchymal stem cells (MSC), but the mechanism is still unclear. Therefore, the aim of this study was to isolate and culture JBMMSCs from surgically derived bone fragments from DOP patients and control patients to investigate the differences in their osteogenic differentiation ability and to elucidate its mechanisms. The results showed that the osteogenic ability of hJBMMSCs was significantly decreased in the DOP environment. Mechanism study showed that the expression of senescence marker gene P53 was significantly increased in DOP hJBMMSCs compared to control hJBMMSCs according to RNA-sequencing result. Further, DOP hJBMMSCs were found to display significant senescence using β-galactosidase staining, mitochondrial membrane potential and ROS assay, qRT-PCR and WB analysis. Overexpression of P53 in hJBMMSCs, knockdown of P53 in DOP hJBMMSCs, and knockdown followed by overexpression of P53 significantly affected the osteogenic differentiation ability of hJBMMSCs. These results suggest that MSC senescence is an important reason for decreasing osteogenic capacity in DOP patients. P53 is a key target in regulating hJBMMSCs aging, and knocking down P53 can effectively restore the osteogenic differentiation ability of DOP hJBMMSCs and promote osteosynthesis in DOP dental implants. It provided a new idea to elucidate the pathogenesis and treatment of diabetic bone metabolic diseases.
Keywords: Bone regeneration; Diabetic osteoporosis; Osteogenesis; Senescence; hJBMMSCs.
©2023PublishedbyElsevierLtd.
Conflict of interest statement
The authors declare no conflict of interest..
Figures








Similar articles
-
Downregulation of DNA methyltransferase-3a ameliorates the osteogenic differentiation ability of adipose-derived stem cells in diabetic osteoporosis via Wnt/β-catenin signaling pathway.Stem Cell Res Ther. 2022 Aug 4;13(1):397. doi: 10.1186/s13287-022-03088-4. Stem Cell Res Ther. 2022. PMID: 35927735 Free PMC article.
-
JKAMP inhibits the osteogenic capacity of adipose-derived stem cells in diabetic osteoporosis by modulating the Wnt signaling pathway through intragenic DNA methylation.Stem Cell Res Ther. 2021 Feb 12;12(1):120. doi: 10.1186/s13287-021-02163-6. Stem Cell Res Ther. 2021. PMID: 33579371 Free PMC article.
-
Decreased autophagy impairs osteogenic differentiation of adipose-derived stem cells via Notch signaling in diabetic osteoporosis mice.Cell Signal. 2021 Nov;87:110138. doi: 10.1016/j.cellsig.2021.110138. Epub 2021 Aug 28. Cell Signal. 2021. PMID: 34461277
-
Application of extracellular vesicles in diabetic osteoporosis.Front Endocrinol (Lausanne). 2024 Dec 10;15:1466775. doi: 10.3389/fendo.2024.1466775. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39720256 Free PMC article. Review.
-
Role of microRNA in Diabetic Osteoporosis.Mol Biotechnol. 2024 Nov 28. doi: 10.1007/s12033-024-01316-1. Online ahead of print. Mol Biotechnol. 2024. PMID: 39609335 Review.
Cited by
-
Protective effects of arecanut seed phenols in retinoic acid induced osteoporosis and the potential mechanisms explored by network pharmacology.Front Endocrinol (Lausanne). 2024 Oct 10;15:1472146. doi: 10.3389/fendo.2024.1472146. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39449745 Free PMC article.
-
Effects of surface nanomorphology on the senescence of periodontal ligament stem cells.Hua Xi Kou Qiang Yi Xue Za Zhi. 2024 Apr 1;42(2):172-180. doi: 10.7518/hxkq.2024.2023244. Hua Xi Kou Qiang Yi Xue Za Zhi. 2024. PMID: 38597077 Free PMC article. Chinese, English.
-
Inhibition of histone methyltransferase G9a promotes the osteogenic potential of bone-derived stem cells in diabetic-osteoporosis by regulating the LINC00657/miR-204-5p/IGFBP5 pathway.Front Endocrinol (Lausanne). 2025 Aug 12;16:1625944. doi: 10.3389/fendo.2025.1625944. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40873948 Free PMC article.
-
Antisenescence therapies for age-related bone loss: Target factors, medicines, biomedical materials.Clin Transl Med. 2025 Jun;15(6):e70350. doi: 10.1002/ctm2.70350. Clin Transl Med. 2025. PMID: 40490937 Free PMC article. Review.
-
Rutin promotes osteogenic differentiation of mesenchymal stem cells (MSCs) by increasing ECM deposition and inhibiting p53 expression.Aging (Albany NY). 2024 Feb 12;16(4):3583-3595. doi: 10.18632/aging.205546. Epub 2024 Feb 12. Aging (Albany NY). 2024. PMID: 38349887 Free PMC article.
References
-
- Saeedi P., Petersohn I., Salpea P., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019;157 doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous